Vertex Pharmaceuticals Incorporated $VRTX Stock Position Decreased by Monetary Management Group Inc.

Monetary Management Group Inc. lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 555 shares of the pharmaceutical company’s stock after selling 50 shares during the period. Monetary Management Group Inc.’s holdings in Vertex Pharmaceuticals were worth $269,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Clal Insurance Enterprises Holdings Ltd grew its position in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 45 shares during the last quarter. Mascagni Wealth Management Inc. bought a new position in Vertex Pharmaceuticals in the 4th quarter worth about $31,000. SJS Investment Consulting Inc. grew its position in Vertex Pharmaceuticals by 46.2% in the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company’s stock worth $46,000 after purchasing an additional 30 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in Vertex Pharmaceuticals in the 1st quarter worth about $46,000. Finally, Stone House Investment Management LLC bought a new position in Vertex Pharmaceuticals in the 1st quarter worth about $48,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $397.46 on Friday. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.88. The stock has a market capitalization of $101.90 billion, a PE ratio of 28.41 and a beta of 0.44. The firm has a 50 day simple moving average of $440.20 and a 200-day simple moving average of $462.13.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. During the same period in the prior year, the business earned ($12.83) earnings per share. The business’s quarterly revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several recent analyst reports. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Scotiabank decreased their target price on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 5th. Royal Bank Of Canada decreased their target price on shares of Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 5th. Morgan Stanley set a $439.00 price objective on shares of Vertex Pharmaceuticals and gave the company an “equal weight” rating in a report on Tuesday, August 5th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $497.10.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.